1. Meropenem: laboratory and clinical data
George Drusano 
Clinical Microbiology and Infection 
Volume 3, Pages 4S51-4S59 (January 1997)
DOI: /S X(14)
Copyright © 1997 European Society of Clinical Infectious Diseases Terms and Conditions

2. Figure 1
Chemical structure of meropenem. 1, Hydroxyethyl moiety in trans configuration confers stability to serine β-lactamases. 2, β-lactam ring provides high affinity for penicillin-binding proteins. 3, Carbapenem nucleus associated with ultra-broad antibacterial spectrum. 4, C1 methyl group improves stability to renal dehydropeptidase-I. 5, C2 moiety enhances activity against Gram-negative pathogens, including Pseudomonas aeruginosa, and may also account for the good central nervous system tolerability of meropenem.
Clinical Microbiology and Infection 1997 3, 4S51-4S59DOI: ( /S X(14) )
Copyright © 1997 European Society of Clinical Infectious Diseases Terms and Conditions

3. Figure 2
Comparative efficacy of meropenem and combination regimens in two separate studies in patients with nosocomial lower respiratory tract infections. Dosages: amikacin 15 mg/kg once daily; meropenem 1 g 8–hourly; ceftazidime 2 g 8–hourly; tobramycin 1 mg/kg 8–hourly. n = number of patients evaluated. *p = 0.04 versus ceftazidime + tobramycin; **p = versus ceftazidime + tobramycin.
Clinical Microbiology and Infection 1997 3, 4S51-4S59DOI: ( /S X(14) )
Copyright © 1997 European Society of Clinical Infectious Diseases Terms and Conditions

4. Figure 3
Efficacy of meropenem and comparators in patients with intra-abdominal infections. CTX, cefotaxime; CLI, clindamycin; IPM/C; imipenem/cilastatin; MEM, meropenem; MTR, metronidazole; TOB, tobramycin; n = number of patients evaluated.
Clinical Microbiology and Infection 1997 3, 4S51-4S59DOI: ( /S X(14) )
Copyright © 1997 European Society of Clinical Infectious Diseases Terms and Conditions